Загрузка...
4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
Abstract Background Omalizumab is licensed as add-on therapy for patients with severe allergic asthma. Response is in most studies scored by the physician’s global evaluation of treatment effectiveness (GETE). A good clinical and validated parameter for treatment response is currently missing. Also,...
Сохранить в:
| Главные авторы: | , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BMC
2017-07-01
|
| Серии: | Allergy, Asthma & Clinical Immunology |
| Предметы: | |
| Online-ссылка: | http://link.springer.com/article/10.1186/s13223-017-0206-9 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|